Cargando…
HMGB3 promotes the malignant phenotypes and stemness of epithelial ovarian cancer through the MAPK/ERK signaling pathway
BACKGROUND: Ovarian cancer, particularly epithelial ovarian cancer (EOC), is the leading cause of cancer-related mortality among women. Our previous study revealed that high HMGB3 levels are associated with poor prognosis and lymph node metastasis in patients with high-grade serous ovarian carcinoma...
Autores principales: | Ma, Hanlin, Qi, Gonghua, Han, Fang, Gai, Panpan, Peng, Jiali, Kong, Beihua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273509/ https://www.ncbi.nlm.nih.gov/pubmed/37328851 http://dx.doi.org/10.1186/s12964-023-01172-7 |
Ejemplares similares
-
HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022) -
PBK drives PARP inhibitor resistance through the TRIM37/NFκB axis in ovarian cancer
por: Ma, Hanlin, et al.
Publicado: (2022) -
TTK inhibition increases cisplatin sensitivity in high-grade serous ovarian carcinoma through the mTOR/autophagy pathway
por: Qi, Gonghua, et al.
Publicado: (2021) -
PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma
por: Ma, Hanlin, et al.
Publicado: (2019) -
FBXO22 Promotes Growth and Metastasis and Inhibits Autophagy in Epithelial Ovarian Cancers via the MAPK/ERK Pathway
por: Li, Minle, et al.
Publicado: (2021)